Loading...
OTCM
IVRN
Market cap0kUSD
Mar 05, Last price  
0.00USD
Name

H-Cyte Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
72.67%
Rev. gr., 5y
16.94%
Revenues
453k
-71.86%
0033,0450207,344818,2118,346,8582,150,6721,611,518453,460
Net income
-15m
L+194.38%
-673,333-2,937,032-6,523,077-16,227,484-6,456,477-4,908,644-29,983,091-7,835,170-4,940,456-14,543,494
CFO
-2m
L-60.21%
-573,736-2,759,875-5,981,944-5,427,468-5,590,467-2,341,164-12,291,275-7,257,743-4,809,810-1,913,738

Profile

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
URL
http://www.hcyte.com/
IPO date
Dec 19, 2014
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
453
-71.86%
Cost of revenue
3,511
Unusual Expense (Income)
NOPBT
(3,058)
NOPBT Margin
Operating Taxes
4,244
Tax Rate
NOPAT
(7,302)
Net income
(14,543)
194.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
402
BB yield
Debt
Debt current
3,923
Long-term debt
1,760
Deferred revenue
Other long-term liabilities
321
Net debt
7,597
Cash flow
Cash from operating activities
(1,914)
CAPEX
Cash from investing activities
469
Cash from financing activities
1,818
FCF
(3,058)
Balance
Cash
(1,914)
Long term investments
Excess cash
Stockholders' equity
(58,889)
Invested Capital
55,472
ROIC
ROCE
89.50%
EV
Common stock shares outstanding
294
Price
Market cap
EV
EBITDA
(3,044)
EV/EBITDA
Interest
368
Interest/NOPBT